Key Insights

Highlights

Success Rate

88% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

9.1%

2 terminated out of 22 trials

Success Rate

87.5%

+1.0% vs benchmark

Late-Stage Pipeline

14%

3 trials in Phase 3/4

Results Transparency

43%

6 of 14 completed with results

Key Signals

6 with results88% success

Data Visualizations

Phase Distribution

9Total
P 1 (1)
P 2 (5)
P 3 (3)

Trial Status

Completed14
Unknown6
Terminated2

Trial Success Rate

87.5%

Benchmark: 86.5%

Based on 14 completed trials

Clinical Trials (22)

Showing 20 of 20 trials
NCT04587323CompletedPrimary

VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease

NCT04417257Phase 2TerminatedPrimary

Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults

NCT05329220Phase 3CompletedPrimary

ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

NCT04830800Phase 1CompletedPrimary

A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC (Phase 1)

NCT06817070CompletedPrimary

Diet, Exercise, and Nutrition Challenges in Mexican Adults During COVID-19: A Study

NCT04472013CompletedPrimary

Systematic Assessment of SARS-CoV-2 Neurotropic Capacity in Modestly and Critically Ill Patients, and Patients Who Died From COVID-19

NCT05077267Phase 2CompletedPrimary

ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects

NCT04347369CompletedPrimary

A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease

NCT04366024CompletedPrimary

A Novel Nomogram to Predict Severity of COVID-19

NCT04642638Phase 2Terminated

Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure

NCT04446377Phase 2CompletedPrimary

A Study of LAM-002A for the Prevention of Progression of COVID-19

NCT05603130CompletedPrimary

Epidemiologic Register on Diabetes and COVID-19 in Tunisia

NCT04682873Phase 3CompletedPrimary

A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus

NCT04787510Completed

COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection

NCT04371354UnknownPrimary

Outcomes of Covid-19 Protective Measures in Endoscopy

NCT04984408Phase 3UnknownPrimary

Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.

NCT04969172Phase 2UnknownPrimary

A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection

NCT04779359UnknownPrimary

Role of Lymphocyte Subsets and Laboratory Measurements in COVID-19 Disease

NCT04757792CompletedPrimary

Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU

NCT04691895UnknownPrimary

Gastrointestinal Symptoms in COVID-19

Scroll to load more

Research Network

Activity Timeline